INTELLECTUAL PROPERTY
EXCLUSIVE PATENTS
2 Patents
BOTH PATENTS HAVE BEEN LICENSED IN EXCLUSIVITY TO MIRAMOON PHARMA
W0 2017/203083A1 – Priority 2016
The patent covers new compounds that are capable of treating or preventing disorders or diseases associated with intracellular calcium dysregulation or Ryanodine receptor dysfunction. The invention also relates to methods for synthesizing our compounds, to pharmaceutical compositions containing them, and to the use thereof for preventing or treating skeletal muscle, heart and nervous system disorders.
Status
Granted in:
Australia; Chile; China; EU; (Austria, Belgium, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Hungary, Luxemburg, Norway, Poland, Portugal, Romania, Spain, Sweden, Switzerland, The Netherlands, Turkey, U.K.); Japan; Mexico; Russia and US;
Pending in:
Canada; India and Israel.
2nd Patent:
A new patent has been submited to the European office with priority date June/2022.
Status
On evaluation process.
For detailed information about the progress of the company or investing options, leave us a message and we will organize a video meeting with your team.
CONTACT PERSON
Pablo Ferrón